BIO Congratulates President-Elect Obama on His Election Victory
"We look forward to working with President-elect Obama, the new Congress and public officials at all levels of government to achieve these goals and continue to build our nation’s innovation economy. Together, we can implement the public policies necessary to help heal, fuel, feed and clean our nation," said Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood following yesterday’s historic U.S. elections. Read the news release.
A Message From Jim
As are people from all walks of life across the country and around the world, the BIO staff - with many different political persuasions represented among us - is looking forward with optimism to the promise and meaning of this historic election. Continue reading.
Valuation, Due Diligence, Negotiation, and Contracts
To compete in today's challenging environment you have to be at your very best. BIO's Advanced Business Development course can help you hone your skills in valuation, due diligence, negotiation and contracts to take your company (and your career) to the next level.
Sign up for the course
Regulatory Affairs Webinar
Building a strong working relationship with the FDA is critical to successful biopharmaceutical development. And, successful biopharmaceutical development is critical for a young company's bottom line. If you are an emerging biotech company executive, regulatory or clinical staff – Participate in this first webinar, Understanding Expectations and Regulatory Speak in Pre-IND to Phase II Stages of FDA Approval Process.
Sign up for the Webinar
Policy Updates
Small Business Innovation Research Grants (SBIR)
Not sure what the SBIR issue is? Check out our Hopes and Cures Blog, and find out why stamping out SBIR will also stamp out hope for cures.
